Zhejiang Zhenyuan Share Co Ltd

Zhejiang Zhenyuan Share Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.93, indicating the company can cover its short-term liabilities with its short-term assets. However, the company reported negative free cash flow of -88.5 million CNY, driven by capital expenditures of -186.2 million CNY, which suggests ongoing investment in operations or expansion. The company's liquidity risk is assessed as medium, with net cash being negative after subtracting total debt. In terms of profitability, Zhejiang Zhenyuan Share Co Ltd reported a return on equity (ROE) of 1.15% and a return on assets (ROA) of 0.77%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's net income of 22.7 million CNY and operating income of 37.7 million CNY indicate modest profitability, with a gross profit of 554 million CNY supporting this. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification beyond the Chinese market. This concentration increases exposure to local economic and regulatory conditions, which could impact revenue stability. Looking ahead, the company's growth trajectory appears to be modest, with no significant revenue growth or decline reported in the most recent financial period. The capital expenditures suggest a focus on maintaining or expanding production capabilities, but the negative free cash flow indicates that the company is not currently generating excess cash to reinvest or return to shareholders. The company's risk profile is characterized by a low dilution risk, with no significant dilution sources identified in the most recent filings. However, the negative free cash flow and capital expenditures suggest that the company may need to raise additional capital in the future, which could introduce dilution pressure. No recent dilution events have been reported, and the company's equity base remains strong at 1.98 billion CNY. There are no recent material events or filings that have significantly impacted the company's operations or financial position. The company's financial statements do not indicate any major legal, regulatory, or operational disruptions in the most recent reporting period.